Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography
- PMID: 35700629
- DOI: 10.1016/j.lungcan.2022.05.005
Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography
Abstract
Objectives: Lung cancer (LC) remains a burden for patients and healthcare systems, with most cases only diagnosed once disease is late stage. Screening for LC with low-dose computed tomography (LDCT) has shown a stage shift and led to a lung cancer-specific mortality reduction. Economic evaluations have been conducted which explore the benefits and costs of screening, however, previous systematic reviews concluded results were heterogeneous. LC screening has evolved and there have been further cost-effectiveness analyses conducted. The aim of this study was to provide an up-to-date systematic review of the cost-effectiveness of LC screening with LDCT.
Methods and materials: Databases were searched for full papers published in English 01/1994-02/2022. Inclusion criteria was full economic evaluation of LC screening using LDCT compared to either no screening or chest X-ray.
Results: Forty-five evaluations were identified, three conducted alongside trials and 42 modelling studies. Thirty-nine evaluations (86.7%) found LC screening with LDCT to be cost-effective. Several findings were broadly consistent across studies: cost-effectiveness was optimal in those age 55-75 years and smoking history of at least 20 pack-years. Biennial screening was often more cost-effective than annual screening and would likely result in less additional findings and radiation exposure. A smoking cessation intervention alongside screening improved cost-effectiveness, but which intervention was optimal was unclear. Risk predictions models using more parameters to target participants for screening did not have more benefits than those using age and smoking alone, and cost-effectiveness was equivalent. Cost-effectiveness was sensitive to cost and specificity of LDCT, and disutility associated with screening.
Conclusion: Overall, LC screening with LDCT is cost-effective in a high-risk population. Questions remain regarding risk prediction models, smoking cessation interventions and appropriateness of utility values in the screened population. Once these uncertainties are addressed, further economic evaluation may be required to inform policymakers prior to implementation.
Keywords: Early detection; Economic evaluation; Lung cancer screening; Systematic review.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Economic evaluation of low-dose computed tomography for lung cancer screening among high-risk individuals - evidence from Hungary based on the HUNCHEST-II study.BMC Health Serv Res. 2024 Dec 3;24(1):1537. doi: 10.1186/s12913-024-11828-w. BMC Health Serv Res. 2024. PMID: 39627793 Free PMC article.
-
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.Pharmacoeconomics. 2023 Apr;41(4):395-411. doi: 10.1007/s40273-022-01238-3. Epub 2023 Jan 20. Pharmacoeconomics. 2023. PMID: 36670332 Free PMC article.
-
Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.JAMA Netw Open. 2022 May 2;5(5):e2213634. doi: 10.1001/jamanetworkopen.2022.13634. JAMA Netw Open. 2022. PMID: 35608858 Free PMC article.
-
Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.Lung Cancer. 2016 Nov;101:98-103. doi: 10.1016/j.lungcan.2016.09.013. Epub 2016 Sep 28. Lung Cancer. 2016. PMID: 27794416
-
[Cost-effectiveness of lung cancer screening worldwide: a systematic review].Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Feb 10;40(2):218-226. doi: 10.3760/cma.j.issn.0254-6450.2019.02.018. Zhonghua Liu Xing Bing Xue Za Zhi. 2019. PMID: 30744276 Chinese.
Cited by
-
Natural history models for lung Cancer: A scoping review.Lung Cancer. 2025 May;203:108495. doi: 10.1016/j.lungcan.2025.108495. Epub 2025 Mar 26. Lung Cancer. 2025. PMID: 40174386 Free PMC article.
-
Current Evidence for a Lung Cancer Screening Program.Port J Public Health. 2024 Apr 22;42(2):133-158. doi: 10.1159/000538434. eCollection 2024 Aug. Port J Public Health. 2024. PMID: 39469231 Free PMC article. Review.
-
Single CT Appointment for Double Lung and Colorectal Cancer Screening: Is the Time Ripe?Diagnostics (Basel). 2022 Sep 27;12(10):2326. doi: 10.3390/diagnostics12102326. Diagnostics (Basel). 2022. PMID: 36292015 Free PMC article. Review.
-
A cost minimization analysis of the implementation of the international lung screening trial in Catalonia (Spain).BMC Health Serv Res. 2025 Jul 30;25(1):1001. doi: 10.1186/s12913-025-13008-w. BMC Health Serv Res. 2025. PMID: 40739558 Free PMC article.
-
Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia.Transl Lung Cancer Res. 2025 Jul 31;14(7):2403-2426. doi: 10.21037/tlcr-2025-296. Epub 2025 Jul 28. Transl Lung Cancer Res. 2025. PMID: 40799423 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical